San Diego, CA - BioMed Realty, a leading provider of real estate solutions to the life science and technology industries, announced that Charlie Piscitello has joined the company as Chief People Officer.

In this role, Mr. Piscitello will lead the Company’s human resource related functions, including talent management, culture, and diversity, equity, and inclusion, reporting to Tim Schoen, CEO of BioMed Realty, and will be based in BioMed Realty’s San Diego headquarters.

Biocair recently spoke at two industry events, Gene Therapy Development & Manufacturing 2023 and On Helix 2023, where the company provided insight on how to mitigate risk in the cell and gene therapy supply chain.

Cambridge, UK - 26 July 2023 - Maxion Therapeutics (“Maxion”), the biotechnology company developing antibody-based drugs for previously untreatable ion channel- and GPCR-driven diseases, is relocating to The Works, Unity Campus, located just outside Cambridge, UK. The company is moving from its previous site at the Babraham Research Campus to an over 7,600 sq ft facility to support further growth.

Welcome News:

One Nucleus welcomes the Government's support of Cambridge to continue developing as a destination to attract global investment and talent in life sciences through plans to create aspirational housing and communities for those employed in the sector.

Housing to Match Aspiration:

Having recently attended the London Stem Cell Conference, Oliver Herd, a trainee patent attorney at IP law firm Appleyard Lees IP LLP, reflects on some of the current activity in the stem cell field and how products, methods and consumables can be protected in Europe.

BioIVT’s standardized collection protocols and diverse donor base help facilitate molecular biomarker validation and ensure their clinical utility.

BioIVT, a global research partner and biospecimen solutions provider for drug and diagnostic development, today announced that it will highlight the integral role it is playing in liquid biopsy research at the American Association for Clinical Chemistry (AACC) Annual Scientific Meeting and Clinical Lab Expo. This conference will be held from July 23-27 at the Anaheim Convention Center in Anaheim, CA.

The Health Systems Task Force is a public-private strategic partnership, bought together by Sir Pascal Soriot, CEO of Astrazenca, which gathers other CEOs and leaders from key stakeholders such as: 

  • GSK

  • Merck KGaA

  • Novo Nordisk

  • Roche

  • Samsung Biologicals

  • Sanofi

  • Karolinska Instituet

  • National Health Service England

  • the Sustainable Healthcare Coalition 


  • The University of Pavia

  • World Health Organizaton (WHO)


Sosei Heptares Acquires Idorsia’s Pharmaceuticals Business in Japan and APAC (ex-China), Accelerating its Transformation into a Fully Integrated Biopharmaceutical Company

The results from Eli Lilly's Phase 3 trial of Donanemab showed that the drug significantly slowed cogntive and functional decline for early symptomatic Alzheimer's disease patients, decreasing their risk of disease progression. Their recent press release stated that "nearly half of participants at earlier stage of disease on donanemab had no clinical progression at 1 year".

This study demonstrates the importance of an early diagnosis and brings hope to people with Alzheimer's disease.